UBS Group
SRPT icon

UBS Group’s Sarepta Therapeutics SRPT Stock Holding History

UBS Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,000
Closed -$129K – 11133
2025
Q4 		$129K Buy
+6,000
New +$126K ﹤0.01% 6780
2024
Q3 		– Sell
-66,700
Closed -$10.5M – 10034
2024
Q2 		$10.5M Buy
+66,700
New +$8.57M ﹤0.01% 2178
2023
Q1 		– Sell
-600
Closed -$77.7K – 10328
2022
Q4 		$77.7K Sell
600
-29,500
-98% -$3.42M ﹤0.01% 6334
2022
Q3 		$3.33M Buy
30,100
+29,500
+4,917% +$2.97M ﹤0.01% 2714
2022
Q2 		$45K Buy
+600
New +$44.1K ﹤0.01% 6004
2020
Q3 		– Sell
-12,100
Closed -$1.94M – 8383
2020
Q2 		$1.94M Buy
+12,100
New +$1.65M ﹤0.01% 2901
2018
Q1 		– Sell
-13,400
Closed -$746K – 8143
2017
Q4 		$746K Hold
13,400
– – ﹤0.01% 4007
2017
Q3 		$608K Sell
13,400
-195,900
-94% -$7.83M ﹤0.01% 4075
2017
Q2 		$7.06M Buy
209,300
+195,900
+1,462% +$6.38M ﹤0.01% 1832
2017
Q1 		$397K Sell
13,400
-35,100
-72% -$1.09M ﹤0.01% 4205
2016
Q4 		$1.33M Sell
48,500
-248,100
-84% -$9.96M ﹤0.01% 3304
2016
Q3 		$18.2M Buy
296,600
+68,100
+30% +$2.06M 0.01% 1042
2016
Q2 		$4.36M Buy
+228,500
New +$4.23M ﹤0.01% 2063
2016
Q1 		– Sell
-25,800
Closed -$995K – 8135
2015
Q4 		$995K Hold
25,800
– – ﹤0.01% 3410
2015
Q3 		$828K Hold
25,800
– – ﹤0.01% 3528
2015
Q2 		$785K Sell
25,800
-1,100
-4% -$22.5K ﹤0.01% 3756
2015
Q1 		$357K Sell
26,900
-37,600
-58% -$501K ﹤0.01% 4406
2014
Q4 		$933K Buy
+64,500
New +$1.09M ﹤0.01% 3627

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's SRPT Position: Q1 2026 in Review

UBS Group increased its Sarepta Therapeutics (SRPT) stake by 8.4% in Q1 2026, buying an estimated $3.36M and bringing the position to 2,232,459 shares worth $48.6M. The position accounts for 0.01% of the portfolio, ranked #1673.

UBS Group first reported a position in SRPT in Q4 2014 and has held it in 46 quarters since. The position peaked at $180M in Q4 2024. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • UBS Group held 2,232,459 shares of Sarepta Therapeutics worth $48.6M as of Q1 2026.
  • UBS Group bought 173,758 Sarepta Therapeutics shares in Q1 2026, an estimated $3.36M.
  • Sarepta Therapeutics made up 0.01% of UBS Group's portfolio in Q1 2026, its #1673 holding.
  • UBS Group first reported a position in Sarepta Therapeutics in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Sarepta Therapeutics position peaked at $180M in Q4 2024.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.